Woodstock Corp Acquires 12,938 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Woodstock Corp lifted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 102.6% during the third quarter, HoldingsChannel reports. The firm owned 25,550 shares of the company’s stock after purchasing an additional 12,938 shares during the quarter. Woodstock Corp’s holdings in Intellia Therapeutics were worth $525,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. raised its stake in Intellia Therapeutics by 1,664.3% in the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after acquiring an additional 1,398 shares during the period. EverSource Wealth Advisors LLC raised its stake in Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after acquiring an additional 1,550 shares during the period. First Horizon Advisors Inc. raised its stake in Intellia Therapeutics by 22.1% in the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after acquiring an additional 472 shares during the period. GAMMA Investing LLC raised its stake in Intellia Therapeutics by 1,322.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,645 shares of the company’s stock valued at $59,000 after acquiring an additional 2,459 shares during the period. Finally, EntryPoint Capital LLC raised its stake in Intellia Therapeutics by 61.1% in the 1st quarter. EntryPoint Capital LLC now owns 4,122 shares of the company’s stock valued at $113,000 after acquiring an additional 1,563 shares during the period. 88.77% of the stock is currently owned by institutional investors.

Intellia Therapeutics Trading Up 4.4 %

Shares of NASDAQ NTLA opened at $18.58 on Monday. Intellia Therapeutics, Inc. has a 12 month low of $17.09 and a 12 month high of $34.87. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of -3.47 and a beta of 1.76. The business has a 50-day moving average of $21.23 and a 200-day moving average of $23.16.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.29). The business had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. Intellia Therapeutics’s quarterly revenue was down 48.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.40) earnings per share. On average, analysts predict that Intellia Therapeutics, Inc. will post -5.22 earnings per share for the current year.

Insiders Place Their Bets

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.00% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NTLA. JPMorgan Chase & Co. lowered their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $54.00 target price on shares of Intellia Therapeutics in a report on Thursday, September 19th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a report on Thursday, June 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Intellia Therapeutics in a report on Monday, June 24th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $73.00 target price on shares of Intellia Therapeutics in a report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $61.77.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.